AXSOME THERAPEUTICS INC (AXSM)

US05464T1043 - Common Stock

90.73  +0.99 (+1.1%)

After market: 91 +0.27 (+0.3%)

Fundamental Rating

2

Taking everything into account, AXSM scores 2 out of 10 in our fundamental rating. AXSM was compared to 193 industry peers in the Pharmaceuticals industry. AXSM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, AXSM is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AXSM has reported negative net income.
In the past year AXSM has reported a negative cash flow from operations.
In the past 5 years AXSM always reported negative net income.
AXSM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of AXSM (-55.38%) is worse than 64.92% of its industry peers.
AXSM has a Return On Equity of -334.73%. This is in the lower half of the industry: AXSM underperforms 76.96% of its industry peers.
Industry RankSector Rank
ROA -55.38%
ROE -334.73%
ROIC N/A
ROA(3y)-81.88%
ROA(5y)-66.39%
ROE(3y)-377.3%
ROE(5y)-252.11%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 91.09%, AXSM belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
AXSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AXSM has been increased compared to 1 year ago.
Compared to 5 years ago, AXSM has more shares outstanding
The debt/assets ratio for AXSM is higher compared to a year ago.

2.2 Solvency

AXSM has an Altman-Z score of 2.36. This is not the best score and indicates that AXSM is in the grey zone with still only limited risk for bankruptcy at the moment.
AXSM's Altman-Z score of 2.36 is fine compared to the rest of the industry. AXSM outperforms 70.68% of its industry peers.
A Debt/Equity ratio of 1.97 is on the high side and indicates that AXSM has dependencies on debt financing.
With a Debt to Equity ratio value of 1.97, AXSM is not doing good in the industry: 79.58% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.97
Debt/FCF N/A
Altman-Z 2.36
ROIC/WACCN/A
WACC9.72%

2.3 Liquidity

A Current Ratio of 2.44 indicates that AXSM has no problem at all paying its short term obligations.
AXSM has a Current ratio (2.44) which is comparable to the rest of the industry.
A Quick Ratio of 2.37 indicates that AXSM has no problem at all paying its short term obligations.
With a Quick ratio value of 2.37, AXSM perfoms like the industry average, outperforming 49.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 2.37

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AXSM have decreased strongly by -44.15% in the last year.
The Revenue has grown by 51.48% in the past year. This is a very strong growth!
EPS 1Y (TTM)-44.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.52%
Revenue 1Y (TTM)51.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%81.27%

3.2 Future

The Earnings Per Share is expected to grow by 35.36% on average over the next years. This is a very strong growth
Based on estimates for the next years, AXSM will show a very strong growth in Revenue. The Revenue will grow by 49.59% on average per year.
EPS Next Y-6.31%
EPS Next 2Y24.66%
EPS Next 3Y37.86%
EPS Next 5Y35.36%
Revenue Next Year43.4%
Revenue Next 2Y55.24%
Revenue Next 3Y60.33%
Revenue Next 5Y49.59%

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AXSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AXSM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

AXSM's earnings are expected to grow with 37.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.66%
EPS Next 3Y37.86%

More info and screens

0

5. Dividend

5.1 Amount

AXSM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (12/20/2024, 8:00:01 PM)

After market: 91 +0.27 (+0.3%)

90.73

+0.99 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)02-18 2025-02-18/amc
Inst Owners81.66%
Inst Owner Change-3.14%
Ins Owners15.66%
Ins Owner Change0.44%
Market Cap4.40B
Analysts86.09
Price Target130.69 (44.04%)
Short Float %17.87%
Short Ratio14.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.03%
Min EPS beat(2)-22.89%
Max EPS beat(2)6.83%
EPS beat(4)1
Avg EPS beat(4)-26.85%
Min EPS beat(4)-74.11%
Max EPS beat(4)6.83%
EPS beat(8)2
Avg EPS beat(8)-10.56%
EPS beat(12)5
Avg EPS beat(12)-4.57%
EPS beat(16)8
Avg EPS beat(16)-1.7%
Revenue beat(2)1
Avg Revenue beat(2)1.05%
Min Revenue beat(2)-1.69%
Max Revenue beat(2)3.79%
Revenue beat(4)3
Avg Revenue beat(4)1.55%
Min Revenue beat(4)-1.69%
Max Revenue beat(4)3.8%
Revenue beat(8)7
Avg Revenue beat(8)35.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.54%
PT rev (3m)2.27%
EPS NQ rev (1m)-10.92%
EPS NQ rev (3m)-10.92%
EPS NY rev (1m)5.02%
EPS NY rev (3m)2.28%
Revenue NQ rev (1m)1.59%
Revenue NQ rev (3m)1.59%
Revenue NY rev (1m)3.11%
Revenue NY rev (3m)1.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.99
P/FCF N/A
P/OCF N/A
P/B 47.33
P/tB 135.89
EV/EBITDA N/A
EPS(TTM)-6.53
EYN/A
EPS(NY)-2.32
Fwd EYN/A
FCF(TTM)-2.74
FCFYN/A
OCF(TTM)-2.74
OCFYN/A
SpS6.98
BVpS1.92
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.38%
ROE -334.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.09%
FCFM N/A
ROA(3y)-81.88%
ROA(5y)-66.39%
ROE(3y)-377.3%
ROE(5y)-252.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 1.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.18%
Cap/Sales 0.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.44
Quick Ratio 2.37
Altman-Z 2.36
F-Score3
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)137.31%
Cap/Depr(5y)142.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.52%
EPS Next Y-6.31%
EPS Next 2Y24.66%
EPS Next 3Y37.86%
EPS Next 5Y35.36%
Revenue 1Y (TTM)51.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%81.27%
Revenue Next Year43.4%
Revenue Next 2Y55.24%
Revenue Next 3Y60.33%
Revenue Next 5Y49.59%
EBIT growth 1Y-58.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.35%
EBIT Next 3Y52.89%
EBIT Next 5Y42.72%
FCF growth 1Y-12.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.55%
OCF growth 3YN/A
OCF growth 5YN/A